Molecular and cellular pathogenesis of benign prostatic hyperplasia
- PMID: 15540721
- DOI: 10.1097/01.ju.0000133655.71782.14
Molecular and cellular pathogenesis of benign prostatic hyperplasia
Abstract
Purpose: Symptomatic benign prostatic hyperplasia (BPH) is one of the most common ailments seen by the urologist. Significant advances have occurred in medical and surgical therapy, and in the understanding of the biology of this disease. However, the basic science literature is often conflicting and confusing, without a unified voice. We report the current state of knowledge of the molecular and cellular basis of BPH.
Materials and methods: We compiled and interpreted basic science studies relevant to BPH pathogenesis.
Results: Cellular alterations that include changes in proliferation, differentiation, apoptosis and senescence in the epithelium and stroma are implicated in BPH pathogenesis. Molecular analyses have yielded numerous candidate genes important in disease progression. Differential expression of cytokines and growth factors in BPH tissue suggests roles for inflammation and hypoxia. Through the use of cell culture models the complex regulatory mechanisms of growth control in BPH are becoming defined.
Conclusions: The scientific endeavor has resulted in great strides in our understanding of BPH on a molecular and cellular level. It is hopeful that basic science and translational research will improve treatment and prevention strategies for this common disease of elderly men.
Similar articles
-
Cell kinetic in epithelium and stroma of benign prostatic hyperplasia.J Urol. 1997 Jul;158(1):217-21. doi: 10.1097/00005392-199707000-00074. J Urol. 1997. PMID: 9186363
-
The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation.Eur Urol. 2011 Jul;60(1):106-17. doi: 10.1016/j.eururo.2011.03.055. Epub 2011 Apr 9. Eur Urol. 2011. PMID: 21497433 Review.
-
Molecular profiling of benign prostatic hyperplasia using a large scale real-time reverse transcriptase-polymerase chain reaction approach.J Urol. 2004 Oct;172(4 Pt 1):1382-5. doi: 10.1097/01.ju.0000137819.92305.46. J Urol. 2004. PMID: 15371850
-
Correlation between benign prostatic hyperplasia and inflammation.Curr Opin Urol. 2013 Jan;23(1):5-10. doi: 10.1097/MOU.0b013e32835abd4a. Curr Opin Urol. 2013. PMID: 23159991 Review.
-
Cellular senescence in the pathogenesis of benign prostatic hyperplasia.Prostate. 2003 Apr 1;55(1):30-8. doi: 10.1002/pros.10204. Prostate. 2003. PMID: 12640658
Cited by
-
Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol).J Endocrinol Invest. 2006 Jul-Aug;29(7):665-74. doi: 10.1007/BF03344169. J Endocrinol Invest. 2006. PMID: 16957418 Review.
-
Involvement of fibroblast growth factor receptor genes in benign prostate hyperplasia in a Korean population.Dis Markers. 2013;35(6):869-75. doi: 10.1155/2013/792941. Epub 2013 Dec 9. Dis Markers. 2013. PMID: 24385678 Free PMC article.
-
Proliferation and phenotypic changes of stromal cells in response to varying estrogen/androgen levels in castrated rats.Asian J Androl. 2009 Jul;11(4):451-9. doi: 10.1038/aja.2009.28. Epub 2009 Jun 1. Asian J Androl. 2009. PMID: 19483715 Free PMC article.
-
Oxidative Stress in Benign Prostatic Hyperplasia: Mechanisms, Clinical Relevance and Therapeutic Perspectives.Diseases. 2025 Feb 11;13(2):53. doi: 10.3390/diseases13020053. Diseases. 2025. PMID: 39997060 Free PMC article. Review.
-
Anti-nociceptive and anti-inflammatory properties of 5alpha-reductase inhibitor finasteride in experimental animals.Eur J Drug Metab Pharmacokinet. 2008 Jul-Sep;33(3):181-6. doi: 10.1007/BF03191116. Eur J Drug Metab Pharmacokinet. 2008. PMID: 19007044
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical